SPECT for risk stratification in patients with advanced liver disease

Jay Talati, David E. Winchester
{"title":"SPECT for risk stratification in patients with advanced liver disease","authors":"Jay Talati,&nbsp;David E. Winchester","doi":"10.1016/j.liver.2023.100181","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients with advanced liver disease (ALD) have unique hemodynamics including high resting cardiac output and low systemic vascular resistance which may reduce the sensitivity of pharmacological myocardial perfusion imaging (MPI). MPI is frequently ordered for patients with ALD if liver transplantation is being considered. Because of the limited data on effectiveness of MPI in the ALD population, we conducted this cohort study focused on cardiac outcomes after pharmacological MPI.</p></div><div><h3>Methods</h3><p>We conducted a cohort study comparing normal versus abnormal MPI among 454 patients with ALD between 1/1/2011 and 06/01/2021 at a single tertiarycare academic medical center. Abnormal MPI was defined as summed stress score &gt; 2 on LVEF &lt; 40 %. The primary outcome was to compare the frequency of major adverse cardiovascular events (MACEs) among ALD patients with and without abnormal MPI. Secondary outcome included individual components of MACE analyzed by chi square. Kaplan-Meier survival curves and a logistic-regression model of associations with MACE were also performed.</p></div><div><h3>Results</h3><p>In this cohort, 58 patients were observed to have an abnormal MPI. Baseline characteristics between the groups were similar, except prior coronary disease, which was more common among the abnormal MPI group (risk ratio 2.07, 95 % confidence interval 1.30–3.30, <em>P</em> = 0.003). MACE was more common in the group with abnormal MPI (<em>n</em> = 24, 41.4 % versus normal MPI <em>n</em> = 104, 26.3 %, <em>P</em> &lt; .001). No difference in MACE was observed when stratified by liver disease type. In the logistic regression model, diabetes mellitus, stage 3 chronic kidney disease, and summed stress score &gt;2 were retained as being associated with MACE.</p></div><div><h3>Conclusions</h3><p>Our data suggest that MPI remains an effective test for identifying ALD patients at higher risk of mortality and cardiac events. Further study is needed to understand whether a strategy of routine MPI for liver transplant candidates effectively improves long term survival.</p></div>","PeriodicalId":100799,"journal":{"name":"Journal of Liver Transplantation","volume":"12 ","pages":"Article 100181"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Liver Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666967623000430","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Patients with advanced liver disease (ALD) have unique hemodynamics including high resting cardiac output and low systemic vascular resistance which may reduce the sensitivity of pharmacological myocardial perfusion imaging (MPI). MPI is frequently ordered for patients with ALD if liver transplantation is being considered. Because of the limited data on effectiveness of MPI in the ALD population, we conducted this cohort study focused on cardiac outcomes after pharmacological MPI.

Methods

We conducted a cohort study comparing normal versus abnormal MPI among 454 patients with ALD between 1/1/2011 and 06/01/2021 at a single tertiarycare academic medical center. Abnormal MPI was defined as summed stress score > 2 on LVEF < 40 %. The primary outcome was to compare the frequency of major adverse cardiovascular events (MACEs) among ALD patients with and without abnormal MPI. Secondary outcome included individual components of MACE analyzed by chi square. Kaplan-Meier survival curves and a logistic-regression model of associations with MACE were also performed.

Results

In this cohort, 58 patients were observed to have an abnormal MPI. Baseline characteristics between the groups were similar, except prior coronary disease, which was more common among the abnormal MPI group (risk ratio 2.07, 95 % confidence interval 1.30–3.30, P = 0.003). MACE was more common in the group with abnormal MPI (n = 24, 41.4 % versus normal MPI n = 104, 26.3 %, P < .001). No difference in MACE was observed when stratified by liver disease type. In the logistic regression model, diabetes mellitus, stage 3 chronic kidney disease, and summed stress score >2 were retained as being associated with MACE.

Conclusions

Our data suggest that MPI remains an effective test for identifying ALD patients at higher risk of mortality and cardiac events. Further study is needed to understand whether a strategy of routine MPI for liver transplant candidates effectively improves long term survival.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SPECT在晚期肝病患者风险分层中的应用
背景晚期肝病(ALD)患者具有独特的血液动力学,包括高静息心输出量和低全身血管阻力,这可能降低药物心肌灌注成像(MPI)的敏感性。如果考虑肝移植,则经常为ALD患者订购MPI。由于MPI在ALD人群中的有效性数据有限,我们进行了这项队列研究,重点关注药物MPI。异常MPI被定义为总应力得分>;2在LVEF上<;40%。主要结果是比较伴有和不伴有MPI异常的ALD患者发生主要心血管不良事件(MACE)的频率。次要结果包括通过卡方分析的MACE的个体成分。还进行了Kaplan-Meier生存曲线和MACE相关性的逻辑回归模型。结果在该队列中,58例患者出现MPI异常。两组之间的基线特征相似,这在MPI异常组中更常见(风险比2.07,95%置信区间1.30-3.30,P=0.003)。MACE在MPI异常的组中更为常见(n=24,41.4%与MPI正常n=104,26.3%,P<;.001)。按肝病类型分层时,MACE没有观察到差异。在逻辑回归模型中,糖尿病、3期慢性肾脏疾病和总应激评分>;2被保留为与MACE相关。结论我们的数据表明,MPI仍然是识别死亡率和心脏事件风险较高的ALD患者的有效测试。需要进一步的研究来了解肝移植候选者的常规MPI策略是否能有效提高长期生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial board Contents Technical refinements to reduce the early biliary complication in living donor liver transplantation Daratumumab as a rescue therapy for antibody-mediated rejection in super-urgent ABO-incompatible pediatric liver transplantation The effects of underlying inflammatory bowel disease on the outcomes of primary sclerosing cholangitis liver transplant recipients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1